An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.
|Articles|August 7, 2006
Payment settlements keep generics off the market
To offset generic drug competition, brand manufacturers are increasingly offering generic companies million-dollar payments to delay cheaper generic alternatives from reaching the market. In the latest settlement, Sanofi-Aventis and Bristol-Myers Squibb offered to pay Canadian generic drugmaker Apotex an estimated $40 million to drop its patent challenge and avoid a trial in exchange for delaying introduction of a generic version of the anti-clotting agent clopidogrel (Plavix) until 2011.
Advertisement
Advertisement
Related to this article
Matthew Crawford, PhD, of the University of Virginia, and Mario Danek of Qnovia explain what pharmacists can do now and what may come next.
The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.
Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.
As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.
Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Advertisement
Advertisement
Trending on Drug Topics
1
COVID-19 Vaccine Lowers Venous Thromboembolism, Mortality Risk
2
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
3
PBM Audit Practices Under Scrutiny: What the House Inquiry Means for Independent Pharmacies
4
AI Prescribing Pilot Places Pharmacists as Final Link in Care
5